This study is a single-center, open label, 4-month study, designed to evaluate the safety and treatment efficacy of RBM-007 in patients with intraretinal or subretinal edema due to previously untreated neovascular AMD. Up to 5 subjects will be randomized to receive study medication. Study treatment will be administered by intravitreal injections.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
5
Sterile solution
Midwest Eye Institute
Indianapolis, Indiana, United States
Macular Edema
Central subfield thickness on optical coherence tomography
Time frame: 3 months
Visual Acuity
Change from Baseline in Best Corrected Visual Acuity
Time frame: 3 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.